Search results: Sage Journals

Open accessResearch articleFirst published September, 2020

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized,Open-Label Clinical Trial

James Thrasher, Sarit Polsky, Lionel Hovsepian [...]

Diabetes Technology & Therapeutics

Restricted accessResearch articleFirst published January, 2021

Fast-Acting Insulin Aspart Use with the MiniMed TM 670G System

Liana Hsu, Bruce Buckingham, Marina Basina [...]

Diabetes Technology & Therapeutics

Free accessResearch articleFirst published January, 2010

Compatibility of Insulin Lispro,Aspart,and Glulisine with the Solo™ MicroPump,a Novel Miniature Insulin Pump

Gil Senesh, Doron Bushi, Avraham Neta [...]

Journal of Diabetes Science and Technology

Open accessResearch articleFirst published April, 2020

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Christoph Kapitza, Leszek Nosek, Wolfgang Schmider [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published April, 2021

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

Kerem Ozer, Alison M. Cooper, Lily P. Ahn [...]

Diabetes Technology & Therapeutics

Restricted accessResearch articleFirst published March, 2007

Insulin as Initial Therapy in Type 2 Diabetes: Effective,Safe,and Well Accepted

Ildiko Lingvay, Polina F. Kaloyanova, Beverley Adams-Huet [...]

Journal of Investigative Medicine

Free accessResearch articleFirst published January, 2010

Siphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance

Howard C. Zisser, Wendy Bevier, Eyal Dassau [...]

Journal of Diabetes Science and Technology

Open accessResearch articleFirst published February, 2020

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published July, 2020

Safety,Immunogenicity,and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Restricted accessResearch articleFirst published July, 2025

Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring–Derived Glycemic Metrics in Hospitalized Inpatients

Sara M. Alexanian, Michael C. Cheney, Jenny C. Bello Ramos [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published September, 2020

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized,Open-Label Clinical Trial

James Thrasher, Sarit Polsky, Lionel Hovsepian [...]

Diabetes Technology & Therapeutics

Restricted accessResearch articleFirst published January, 2021

Fast-Acting Insulin Aspart Use with the MiniMed TM 670G System

Liana Hsu, Bruce Buckingham, Marina Basina [...]

Diabetes Technology & Therapeutics

Free accessResearch articleFirst published January, 2010

Compatibility of Insulin Lispro,Aspart,and Glulisine with the Solo™ MicroPump,a Novel Miniature Insulin Pump

Gil Senesh, Doron Bushi, Avraham Neta [...]

Journal of Diabetes Science and Technology

Open accessResearch articleFirst published April, 2020

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Christoph Kapitza, Leszek Nosek, Wolfgang Schmider [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published April, 2021

Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

Kerem Ozer, Alison M. Cooper, Lily P. Ahn [...]

Diabetes Technology & Therapeutics

Restricted accessResearch articleFirst published March, 2007

Insulin as Initial Therapy in Type 2 Diabetes: Effective,Safe,and Well Accepted

Ildiko Lingvay, Polina F. Kaloyanova, Beverley Adams-Huet [...]

Journal of Investigative Medicine

Free accessResearch articleFirst published January, 2010

Siphon Effects on Continuous Subcutaneous Insulin Infusion Pump Delivery Performance

Howard C. Zisser, Wendy Bevier, Eyal Dassau [...]

Journal of Diabetes Science and Technology

Open accessResearch articleFirst published February, 2020

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Open accessResearch articleFirst published July, 2020

Safety,Immunogenicity,and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial

Satish K. Garg, Karin Wernicke-Panten, Marek Wardecki [...]

Diabetes Technology & Therapeutics

Restricted accessResearch articleFirst published July, 2025

Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring–Derived Glycemic Metrics in Hospitalized Inpatients

Sara M. Alexanian, Michael C. Cheney, Jenny C. Bello Ramos [...]

Diabetes Technology & Therapeutics